The Primary Prevention of Atherosclerotic Cardiovascular Disease with Statin Therapy

 .

Abstract

It’s unsure whether using a cardiovascular genetic risk score (cGRS) to target statin initiation in the primary prevention of atherosclerotic
cardiovascular disease enhances clinical decision making or health outcomes (ASCVD). Our goal was to calculate the cost-effectiveness of
cGRS testing in guiding therapeutic decisions about statin commencement in people with a low-to-intermediate (2.5 percent–7.5 percent)
10-year ASCVD risk. For low- to intermediate-risk patients, testing for a 27-single-nucleotide polymorphism cardiovascular genetic risk score
is often not a cost-effective technique for focusing statin medication in the primary prevention of atherosclerotic cardiovascular disease. The
cost-effectiveness of cardiovascular genetic risk score testing is influenced by assumptions regarding statin disutility and cost, as well as age,
gender, 10-year atherosclerotic cardiovascular disease risk, and willingness-to-pay threshold.

 .